Hindsight 20/20: Raymond Cohen

18 Aug 2017

• By Tina Tan

Hindsight 20/20 is a new Q&A feature where medtech industry veterans share their long experience taking diverse businesses – be they start-ups or publicly-listed entities – from strength to strength and navigating through times of crises. This first instalment shines the spotlight on Raymond Cohen, who is currently CEO of venture-backed sacral neuromodulation company Axonics Modulation Technologies, Inc. The advice he gives includes not rushing into clinical studies too soon, try to go big with the fundraising and be very cautious when tackling a complex market like the US, among other things.

With around three decades of experience in the medical device industry, Raymond Cohen is recognized for having led several start-ups developing disruptive, technological innovations to growth and has also sat on the board of various publicly-listed entities. He is currently CEO of Axonics Modulation Technologies Inc., a California company developing a rechargeable sacral neuromodulation technology to treat urinary and fecal dysfunction. He recently took the firm through a $35m series C financing round. He was previously CEO of other neuromodulation companies including renal denervation firm Vessix Vascular Inc. , which was acquired by Boston Scientific for $425m in 2013.

Cohen's experience stretches beyond the US, having been on the board of directors of several European firms in the cardiovascular...